Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
Open Access
- 17 July 2013
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 36 (Supplement), S127-S138
- https://doi.org/10.2337/dcs13-2011
Abstract
No abstract availableThis publication has 190 references indexed in Scilit:
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutideInternational Journal of Obesity, 2011
- Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerolDiabetologia, 2011
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trialThe Lancet, 2010
- Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009Diabetologia, 2010
- Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trialThe Lancet, 2010
- Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysisDiabetologia, 2010
- Cardiovascular Outcomes in Trials of Oral Diabetes Medications - A Systematic ReviewArchives of Internal Medicine, 2008
- Rosiglitazone RECORD study: glucose control outcomes at 18 monthsDiabetic Medicine, 2007
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitusDiabetologia, 2006
- Early Metabolic Defects in Persons at Increased Risk for Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1989